Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing new T cell-based immunotherapies for blood cancers and solid tumors. The company's Multi Antigen Recognizing ("MAR")-T cell technology is designed to identify and destroy diverse tumors without genetic modification. This technology expands natural tumor-specific T cells from a patient's or donor's blood that can recognize a wide range of tumor associated antigens, or TAAs. Unlike other T cell therapies, MAR-T cells can recognize hundreds of different epitopes within up to six tumor-specific antigens, providing broad anti-tumor activity. By targeting multiple antigens simultaneously, the therapy uses the natural ability of T cells to recognize and kill tumor targets via native T cell receptors ("TCR"), which also helps limit tumor adaptation or escape. When infused, MAR-T cells are designed to kill cancer cells expressing the TAA. Marker Therapeutics licensed the MAR-T cell technology from Baylor College of Medicine, or BCM, in March 2018. BCM previously used the therapy in seven exploratory clinical trials, treating over 150 patients with various cancers, including lymphoma, multiple myeloma, acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, pancreatic cancer, breast cancer, and various sarcomas. In these studies, BCM observed clinical benefit, expansion of infused cells, and reduced toxicity compared to other cellular therapies. The company is advancing two product candidates for three clinical indications within its MAR-T cell program: an autologous MAR-T cell product (MT-601) for lymphoma and pancreatic cancer, and an Off-the-Shelf ("OTS") product (e.g., MT-401-OTS) for various indications such as AML or MDS. Marker Therapeutics does not genetically engineer its MAR-T cell therapies.